Kinnate Biopharma (Kinnate Biopharma) Effective Interest Rate on Debt % : 0.00% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Kinnate Biopharma Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Kinnate Biopharma's annualized positive value of Interest Expense for the quarter that ended in Dec. 2023 was $0.00 Mil. Kinnate Biopharma's average total debt for the quarter that ended in Dec. 2023 was $3.28 Mil. Therefore, Kinnate Biopharma's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 was 0.00%.

Kinnate Biopharma Effective Interest Rate on Debt % Historical Data

The historical data trend for Kinnate Biopharma's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kinnate Biopharma Effective Interest Rate on Debt % Chart

Kinnate Biopharma Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Effective Interest Rate on Debt %

Get a 7-Day Free Trial

Kinnate Biopharma Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Effective Interest Rate on Debt %	Get a 7-Day Free Trial														-	-	-	-	-

Competitive Comparison of Kinnate Biopharma's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Kinnate Biopharma's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kinnate Biopharma's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kinnate Biopharma's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Kinnate Biopharma's Effective Interest Rate on Debt % falls into.

Kinnate Biopharma Effective Interest Rate on Debt % Calculation

Kinnate Biopharma's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (A: Dec. 2022 )	+	Total Debt (A: Dec. 2023 ))	/ count )
=	-1 * 0	/	( (4.182	+	3.175)	/ 2 )
=	-1 * 0	/	3.6785
=	0.00 %

where

	Total Debt (A: Dec. 2022 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	3.191	+	0.991
=	4.182

	Total Debt (A: Dec. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	2.283	+	0.892
=	3.175

Kinnate Biopharma's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (Q: Sep. 2023 )	+	Total Debt (Q: Dec. 2023 ))	/ count )
=	-1 * 0	/	( (3.384	+	3.175)	/ 2 )
=	-1 * 0	/	3.2795
=	0.00 %

where

	Total Debt (Q: Sep. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	2.515	+	0.869
=	3.384

	Total Debt (Q: Dec. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	2.283	+	0.892
=	3.175

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Dec. 2023) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

Kinnate Biopharma (NAS:KNTE) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

Kinnate Biopharma Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Kinnate Biopharma's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.

Kinnate Biopharma (Kinnate Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kinnate Biopharma Inc (NAS:KNTE) » Definitions » Effective Interest Rate on Debt %

Comparable Companies

Traded in Other Exchanges

N/A

Address

103 Montgomery Street, Suite 150, The Presidio of San Francisco, San Francisco, CA, USA, 94129

Website

https://www.kinnate.com

Kinnate Biopharma Inc is a clinical-stage precision oncology company focused on the discovery, design, and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. The company's pipeline product candidates are; exarafenib (KIN-2787), which is a Rapidly Accelerated Fibrosarcoma (RAF) inhibitor in development for the treatment of patients with lung cancer, melanoma, and other solid tumors, and KIN-3248, a Fibroblast Growth Factor Receptors (FGFR) inhibitor, designed for the treatment of patients with intrahepatic cholangiocarcinoma (ICC), a cancer of the bile ducts in the liver, and urothelial carcinoma (UC), a cancer of the bladder lining, as well as other solid tumors.

Executives

James B. Tananbaum	director, 10 percent owner	3052 PACIFIC AVENUE, SAN FRANCISCO CA 94115
Foresite Capital Fund Iv, L.p.	10 percent owner	600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Orbimed Advisors Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Carl L Gordon	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Jill Desimone	director	C/O PRAXIS PRECISION MEDICINES, INC., 99 HIGH STREET, 30TH FLOOR, BOSTON MA 02110
Orbimed Asia Gp Iv, L.p.	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK, NY 10022
Orbimed Advisors Iv Ltd	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Viii Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629
Richard Thomas Williams	officer: Chief Medical Officer	C/O KINNATE BIOPHARMA INC., 11975 EL CAMINO REAL, SUITE 101, SAN DIEGO CA 92130
Orbimed Capital Gp Vii Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Genesis Gp Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Helen Sabzevari	director	20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Neha Krishnamohan	officer: Chief Financial Officer	12707 HIGH BLUFF DRIVE, SAN DIEGO CA 92130
Dean J Mitchell	director	C/O BRISTOL MYERS SQUIBB CO, 345 PARK AVE, NEW YORK NY 10164